Detalhe da pesquisa
1.
A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative.
Support Care Cancer
; 31(12): 628, 2023 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37828258
2.
Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients.
J Neurooncol
; 145(3): 531-540, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31679112
3.
The evolution of value with filgrastim in oncology.
Future Oncol
; 15(13): 1525-1533, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30835142
4.
Meta-analysis comparing incidence of grade 3-4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung cancer.
Future Oncol
; 15(18): 2163-2174, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31116035
5.
Safety analysis of proposed pegfilgrastim biosimilar in Phase I and Phase III studies.
Future Oncol
; 15(12): 1313-1322, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30834780
6.
Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study.
Future Oncol
; 15(8): 897-907, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30827127
7.
Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study.
Support Care Cancer
; 27(6): 2301-2312, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30343410
8.
Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study.
BMC Nephrol
; 20(1): 81, 2019 03 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30836953
9.
Treatment patterns and outcomes in patients with non-small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropaenia: Results from the MONITOR-GCSF study.
Eur J Cancer Care (Engl)
; 28(4): e13034, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30968997
10.
Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.
Oncologist
; 23(4): 403-409, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29317553
11.
Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study.
BMC Cancer
; 18(1): 917, 2018 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-30249215
12.
MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis.
Eur J Haematol
; 100(3): 241-246, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29171913
13.
Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 studyâ©.
Clin Nephrol
; 89 (2018)(1): 1-9, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29168688
14.
Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials.
Future Oncol
; 13(16): 1385-1393, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28453299
15.
Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study.
Support Care Cancer
; 25(6): 1819-1828, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28111718
16.
Evaluation of the safety and immunogenicity of subcutaneous HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in predialysis and dialysis patientsâ©.
Clin Nephrol
; 88(10): 190-197, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28766493
17.
Medical Affairs and Innovative Medicinal Product Strategy Development.
Pharmaceut Med
; 36(2): 71-82, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35279795
18.
Early access provision: Awareness, educational needs and opportunities to improve oncology patients' access to care.
Front Oncol
; 12: 714516, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36387084
19.
Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare Cancers.
Front Oncol
; 11: 636561, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33763370
20.
CD95L and Anti-Tumor Immune Response: Current Understanding and New Evidence.
Cancer Manag Res
; 13: 2477-2482, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33758545